Abstract 669P
Background
Tumor-targeted drug delivery technologies are urgently needed to overcome conventional chemotherapy’s lack of tumor selectivity. Alphalex conjugates, which contain a pH-low insertion peptide (pHLIP), a linker and a payload are designed to overcome this lack of selectivity. Alphalex PDCs target tumors in an antigen-independent manner. At pH 7.4, the peptide is unstructured. In the low pH tumor microenvironment the peptide forms an alpha helix and inserts directionally into the tumor cell membrane delivering the linker and payload. For CBX-12 the payload is exatecan.
Methods
In this Phase 1 trial, cohorts of pts were treated with escalating doses of CBX-12 in a 3 + 3 design. The primary objectives are safety, tolerability and to determine the MTD/RP2D. Secondary and exploratory objectives include evaluation of plasma PK of CBX-12 and exatecan, anti-tumor activity per RECIST v1.1, and measurement of anti-drug antibodies.
Results
Enrollment is complete with 69 pts having been treated on study. The most frequent treatment-related AEs (TRAEs) were anaemia (53.6%), leukopenia (42.0%), neutropenia (40.6%), nausea (39.1%), and fatigue (36.2%). The most frequent Gr3/4 TRAEs were neutropenia, (27.5%), anaemia (24.6%), leukopenia (21.7%), and thrombocytopenia (13.0%). No ILD or ophthalmic toxicity was reported. There were 5 confirmed responses in ovarian (2), breast (2), and colorectal cancer (1). Evidence of activity was also seen in NSCLC, cholangiocarcinoma, and thymic cancer. Of 12 patients with ovarian cancer there was one confirmed complete response, one confirmed partial response (PR) and tw0 unconfirmed PRs. 8 of 12 saw clinical benefit. The RP2D was established as 125mg/m2 every 21 days.
Conclusions
Tumor targeting facilitated by this pH sensitive peptide made possible an improved safety profile despite the administration of a 5-fold increase in the dose of exatecan compared to unconjugated exatecan. The dose limiting toxicity is myelosuppression. CBX-12 demonstrated broad activity with 5 confirmed responses in three malignancies. A randomized Phase 2 study in platinum resistant ovarian cancer is underway comparing two doses on the once every 21 day schedule.
Clinical trial identification
NCT04902872.
Editorial acknowledgement
Legal entity responsible for the study
Cybrexa Inc.
Funding
Cybrexa Inc.
Disclosure
F. Meric-Bernstam: Financial Interests, Personal and Institutional, Funding: Cybrexa, Inc. P. Pearson: Financial Interests, Personal, Financially compensated role, Consultant: Cybrexa, Inc. M.N. Needle: Financial Interests, Personal, Full or part-time Employment: Cybrexa, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
672P - Inference failure with synthetic arms: Empirical application to phase III oncology trials
Presenter: Alexander Decruyenaere
Session: Poster session 01
673P - Project Optimus for dose optimization: Implementation strategies for your trial from the statistician’s standpoint
Presenter: Miguel Pereira
Session: Poster session 01
674P - Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs
Presenter: Sebastian Albers
Session: Poster session 01
675P - Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer)
Presenter: Lin Shen
Session: Poster session 01
678TiP - A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations
Presenter: Charlotte Lemech
Session: Poster session 01
679TiP - Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors
Presenter: Debashis Sarker
Session: Poster session 01
680TiP - A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
Presenter: Anna Minchom
Session: Poster session 01
681TiP - A phase I/II, open label, multi-center, non-randomized dose escalation and dose expansion study of AMXI-5001 in patients with advanced malignancies
Presenter: Lee Rosen
Session: Poster session 01
682TiP - A phase I, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Presenter: Shigehiro Koganemaru
Session: Poster session 01